"In a number of states across the country, there is
backlash building against [pharmaceutical] sales and marketing," says Ken Johnson, senior vp for the Pharmaceutical Research and Manufacturers of America. As a result, Johnson says the industry trade
group will examine how its members bring medications to market, but he stops short of calling PhRMA's move a task force or committee.
Cynics wonder if this isn't the same halfhearted path PhRMA traveled in August 2005, when it issued its DTC ad guidelines--a 15-point code of conduct that shied away from mandates on the most serious issues, including a one- or two-year moratorium on advertising drugs newly approved by the FDA.
advertisement
advertisement